Heritable mutations in the tumor suppressor gene BRCA1 increase a woman's lifetime risk of developing breast and ovarian cancer. BRCA1's tumor suppressor function is directly linked to its myriad of functions in the cellular response to DNA double-strand breaks (DSBs). BRCA1 interacts with an extensive array of DNA damage responsive proteins and plays important roles in DSB repair, mediated by the homologous recombination pathway, and in the activation of cell cycle checkpoints. However, the role of BRCA1 in the other two DSB repair pathways, classical non-homologous end-joining (C-NHEJ) and alternative NHEJ (A-NHEJ), remains unclear. In this review, we will discuss the current literature on BRCA1's potential role(s) in modulating both C-NHEJ and A-NHEJ. We also present a model showing that BRCA1 contributes to genomic maintenance by promoting precise DNA repair across all cell cycle phases via the direct modulation of DNA end-joining.
BRCA1 and breast cancer
Breast cancer is one of the deadliest and most common cancers affecting women. Although ∼90% of breast cancers occur sporadically, ∼2% are genetically linked to heritable mutations in the breast cancer associated gene 1 (BRCA1) [1] . Germline mutations in BRCA1 confer increased susceptibility to developing breast cancer, with a lifetime risk of ∼80% [2] . Mutations in the BRCA1 gene also result in an elevated risk for various other types of cancer in women, including ovarian, fallopian tube and peritoneal cancer. In addition, these mutations are associated with an increased risk of pancreatic cancer in women and men, and surprisingly an elevated risk for prostate and breast cancer in men [2] [3] [4] [5] [6] . The human BRCA1 gene is located on chromosome 17, specifically at 17q21; it consists of 24 exons and encodes for a protein of 1863 amino acids (1812 in mice) [7] . BRCA1 is also known to encode at least two additional smallersized variant proteins due to alternate splicing [8] [9] [10] [11] . The mature, full-length protein is located in the nucleus and comprises multiple functional domains, including an N-terminal RING finger domain, two nuclear localization signals, an 'SQ' cluster containing several serine and threonine residues that can be phosphorylated, a coiled-coiled domain, and C-terminal tandem BRCA1 C-terminus (BRCT) domains ( Fig. 1) [12, 13] . The majority of BRCA1's functions are mediated by its zinc-binding RING finger motif that forms an enzymatically active E3 ubiquitin-protein ligase when it heterodimerizes with BRCA1-Associated RING Domain 1 (BARD1) and the tandem BRCT domain, which facilitates numerous protein-protein interactions via binding to phosphorylated serines. The importance of these two domains is underscored by the fact that a significant number of breast cancer predisposition mutations are located in these two domains [14] .
fibroblasts (MEFs) deficient in BRCA1 exhibit evidence of extensive genomic instability, including patterns of aneuploidy, centrosomal amplification, and chromosomal aberrations [1, 11, 15, 16] . BRCA1 primarily promotes genomic stability via its numerous functions in the cellular response to DNA double-strand breaks (DSBs). DSBs are deleterious DNA lesions that may lead to gene mutations, senescence, apoptosis, mitotic cell death, genomic instability, and tumorigenesis if misrepaired or left unrepaired [17] . An immediate and complex cellular response to DSBs drives multiple processes, including modulation of the cell cycle, a number of signaling cascades collectively known as the DNA damage response (DDR), and repair pathways that correct the DNA lesion [18] . DSBs are repaired by three major pathways in mammalian cells: the error-free and accurate homologous recombination (HR) pathway, the error-prone but relatively precise classical non-homologous end-joining (C-NHEJ) pathway, and the error-prone alternate non-homologous end-joining (A-NHEJ) pathway [19] . HR repairs DSBs by utilizing a DNA template, typically via a homologous sister chromatid in the S or G2 phases of the cell cycle, to drive repair. C-NHEJ mediates the direct re-ligation of the broken DNA molecule, and is active throughout the cell cycle, partly due to lack of constraints such as the requirement of a DNA template for repair completion [20] . A-NHEJ is active in all phases of the cell cycle, backing up the other two pathways [21] . It is an error-prone process due to its propensity to utilize microhomologies distant from the DSB to mediate repair, which results in deletions. Collectively, these DNA repair mechanisms are responsible for fixing the countless insults our genomes are exposed to, including those induced both by fault (ionizing radiation (IR)-induced DSBs, replication errors, etc.) and by design (V(D)J recombination).
BRCA1 plays a multifaceted role in the cellular response to DNA damage, including modulation of DSB repair and activation of cell cycle checkpoints. The first evidences of BRCA1 involvement in DSB repair came from studies showing that upon irradiation (IR), BRCA1 is hyperphosphorylated and forms discrete nuclear foci that co-localize with the HR factors Rad51 and BRCA2 [22, 23] . BRCA1 primarily functions as a mediator in the cellular response to DNA damage; it serves as a scaffold protein that recruits multiple repair proteins to the DSB via the formation of multiprotein complexes [24] . These distinct multiprotein complexes function in specific processes in the DNA damage response, in particular those that influence DSB repair. BRCA1-specific complexes include the following: (i) a complex with the BRCA1 interacting protein C-terminal helicase 1 (BRIP, also called FANCJ or BACH1) that inhibits C-NHEJ and promotes HR; (ii) a complex with the CtBP-interacting protein (CtIP) and MRE11-RAD50-NBS1 (MRN) that promotes DNA end resection, a prerequisite for the onset of HR; (iii) a complex with BRCA2, PALB2 and Rad51 that is required for DNA strand invasion for HR; and (iv) a complex with Rap80 and Abraxas that blocks aberrant DNA end resection to promote genomic stability [24] . Collectively, these BRCA1 complexes indicate a role for BRCA1 in promoting high-fidelity repair of DSBs, in particular by promoting HR. The positive influence of BRCA1 on HR is supported by studies showing that BRCA1-deficient cells are sensitive to IR and DNA cross-linking agents, which both produce DNA damage that is repaired by HR. Additionally, BRCA1-deficient cells also display increased frequency of chromatid breaks, which are frequently observed in HR-deficient cells [16] . Finally, BRCA1 deficiency leads to a reduction in HR repair, as evaluated by reporter assays, in both human and mouse cells [25, 26] . The role of BRCA1 in the HR pathway has been thoroughly dissected and properly reviewed by a number of groups [12, 13, 27] . BRCA1 also influences the cellular response to DNA damage by modulating the cell-cycle checkpoints in response to DSBs. Following DSB induction, BRCA1 is phosphorylated by the ataxia telangiectasia mutated (ATM) kinase at serine residues 1387 and 1423, and these phosphorylation events are required for activation of the S and G2/M checkpoints, respectively [28, 29] . Furthermore, the BRCA1-BARD1 interaction is important for ATM and ataxia telangiectasia and Rad 3-related (ATR)-mediated phosphorylation of p53 at serine 15 following IR-or UV-induced DNA damage to activate the G1/S checkpoint [30] . Although it is well established that BRCA1 plays an important role in the cellular response to DSBs, in particular HR, the role of BRCA1 in C-NHEJ and A-NHEJ remains a conundrum [31, 32] . Over the years, conflicting evidence pertaining to BRCA1's role in each pathway has added to the mystery. These aspects will be presented and discussed in detail in this review.
BRCA1 in C-NHEJ
Significant effort has also been directed at uncovering a role for BRCA1 in C-NHEJ. One study showed that extracts derived from BRCA1-null MEFs exhibit significantly reduced end-joining activity • BRCA1 in DNA end-joining compared with MEFs with wild-type BRCA1, providing initial insight into BRCA1's function in C-NHEJ [33] . Similarly, whole-cell extracts from the human BRCA1-defective cell line HCC1937 had significantly reduced C-NHEJ activity compared with control cell extracts [34] . However, a number of studies suggest that BRCA1 is not required for C-NHEJ. For example, no discernible defect in DNA DSB rejoining was observed in HCC1937 cells when assayed by pulsed-field gel electrophoresis (PFGE) [35, 36] . Furthermore, in vitro NHEJ assays performed on a host of sporadic breast cancer and BRCA1-deficient cell lines revealed no major overall repair deficiency and demonstrated similar end-joining efficiencies and accuracies [37] . This glut of conflicting data has made it difficult to clearly define a role for BRCA1 in C-NHEJ. The contradictory results are likely due to variations in the assays used, differences in cell lines, and/or differences in the cell cycle phases when the assays were performed [31] .
Closer analyses of the end-joining events revealed that BRCA1 is required for precise end-joining [34, 38, 39] . This was supported by a study showing that siRNA-mediated knockdown of BRCA1 reduced the frequency of precise ligation by C-NHEJ in chromosomally induced DSBs [40] . The decrease in precise repair in the BRCA1-deficient cells was similar to that observed when the C-NHEJ components Ku70, XRCC4 and Ligase IV were knocked down [40] . Furthermore, BRCA1 knockdown increased the proportion of deletions relative to knockdown of the NHEJ components, indicating that BRCA1 not only promotes precise end-joining, but may also divert some DSBs away from end-joining by precise C-NHEJ. Expression of the BRCA1Δ14-15 splice variant or downregulation of wild-type BRCA1 in the breast cancer cell line MCF-7 led to a reduction in the overall, as well as precise, end-joining efficiency, indicating that expression of this splicing variant has a dominant negative effect on the efficiency and fidelity of C-NHEJ [41] . Overexpression of the other BRCA1 splicing variant, termed BRCA1Δ17-19, lacking a portion of the BRCT domain that enables its interaction with critical DNA end-processing factors including CtIP and Abraxas, resulted in delayed dynamics of IR-induced BRCA1 foci formation, impaired HR, and undermined C-NHEJ activity [41] . Finally, decreased fidelity in DNA end-joining was observed in lymphoblastoid cell lines from breast cancer patients harboring a BRCA1 missense mutation [38, 42] .
To follow up on the intriguing results of BRCA1 regulating precise end-joining, several studies were directed at determining how BRCA1 mediates/influences C-NHEJ. Phosphorylation of BRCA1 by Chk2 at serine 988 plays a role in promoting precise end-joining [43, 44] . BRCA1 is also phosphorylated by ATM kinase in response to DSBs, and ATM-mediated phosphorylation of BRCA1 at serine 1423 and serine 1524 was found to be important for precise end-joining activity by C-NHEJ [43] . It was also reported that the N-terminal fragment of BRCA1 (1-304 aa), containing the RING finger domain, accumulates and dissociates rapidly after laser irradiation-induced damage and that this fast association with DSBs is dependent on the C-NHEJ factor Ku80 [45] . The BRCA1-Ku interaction and the rapid recruitment of BRCA1 to DSBs were abolished via cancer causing missense mutations in the RING finger domain. This finding suggests that this interaction is important in BRCA1's ability to promote genomic stability [45] . However, another study reported that amino acids 262-803, but not amino acids 1-200 of BRCA1, mediates the interaction between BRCA1 and Ku80 [7] . The authors found that BRCA1 stabilizes Ku80 binding to chromosomal breaks in G1 phase. In addition, knockdown of BRCA1 resulted in a significant reduction in C-NHEJ in G1 phase cells, with no effect in G2/S phase cells. Collectively, the data in the literature suggests that interaction of BRCA1 with the C-NHEJ factor Ku80 stabilizes the Ku heterodimer at DSBs and that this is required for precise end-joining repair by C-NHEJ in G1 phase of the cell cycle.
BRCA1 in Alt-NHEJ
BRCA1, as a regulator of genomic stability, has been shown to mostly influence DSB repair processes, such as HR and precise end-joining, involved in precise ligation/repair of the broken DNA strand. However, a few reports have suggested that this may not be entirely true, as BRCA1 has been shown to positively influence the inherently error-prone A-NHEJ pathway. First, BRCA1 null MEFs exhibited a 50-100-fold deficiency in microhomology-mediated end-joining (MMEJ)/A-NHEJ of a defined chromosomal DSB [42] . Furthermore, a recent study found that BRCA1 in conjunction with CtIP are required for telomeric fusions in TRF2-depleted cells (uncapped telomeres), independent of Ku80/Ligase IV (C-NHEJ), but dependent on PARP1/Ligase III, well known components of A-NHEJ [10] . BARD1, an interaction partner of BRCA1, was shown to mediate the rapid recruitment of BRCA1 to DNA damage sites [9] . The tandem BRCT domains of BARD1 were found to be a poly ADP-ribose (PAR) binding module, and binding of the BARD BRCTs to PAR targets the BRCA1/BARD1 heterodimer to DNA damage sites. PARs are linked to proteins via PAR polymerases (PARPs), with PARP1 being a factor required for A-NHEJ [21] . PARP1 inhibition suppresses the early recruitment of the BRCA1/BARD1 complex to DNA lesions, suggesting that the A-NHEJ pathway may influence BRCA1's recruitment to DSBs.
In contrast, a significant amount of data suggests that BRCA1 blocks A-NHEJ. Knockdown or loss of BRCA1 protein resulted in an increased frequency of overall plasmid DNA mutagenesis and microhomology-mediated end-joining (MMEJ)/A-NHEJ following DSB induction [46] . Furthermore, inhibition of the exonuclease activity of the DNA end processing and A-NHEJ factor, Mre11, with the specific inhibitor mirin significantly decreased the occurrence of A-NHEJ/MMEJ, but did not considerably affect the overall mutagenic frequency of plasmid DSB repair [46] . These results suggest that BRCA1 protects DNA from mutagenesis during nonhomologous DSB repair. BRCA1 is also known to interact with BRIP1, and disruption of the BRCA1-BRIP1 complex through mutation in BRIP1 compromised C-NHEJ and accelerated errorprone A-NHEJ/MMEJ [47] . Furthermore, disruption of the integrity of the BRIP1 helicase domain resulted in a modest decrease in extrachromosomal (but not intrachromosomal) A-NHEJ/MMEJ. We propose that BRCA1 typically blocks A-NHEJ, but may promote error-prone repair when C-NHEJ is absent and/or inhibited, like at clustered or complex lesions and telomeric DSBs, circumstances when repair of the broken DNA ends takes precedence over restoring sequence accuracy.
BRCA1 influences C-NHEJ in a cell cycle-specific manner
We propose that BRCA1 promotes genomic stability by modulating multiple DSB repair pathways in a cell cycle-specific manner. First, i20 • J. Saha and A.J. Davis BRCA1 promotes HR, the prominent DSB repair pathway in S/G2 phases [12, 13] . As BRCA1 positively influences HR, BRCA1 is believed to primarily be biologically active in S and G2 phases of the cell cycle. This is supported by early studies showing that BRCA1 expression is extremely low in G1 phase, but high in S and G2 phases [48, 49] . However, BRCA1 expression is normal in G1 in cycling cells, suggesting that BRCA1 expression is only low in G1 phase when cells are contact inhibited [50] . It was found that two circuits, the pro-HR factors BRCA1/CtIP and the pro-C-NHEJ factors 53BP1/RIF1, influence each other antagonistically, with BRCA1/ CtIP displacing 53BP1/RIF1 from DSBs in S phase to allow DNA end resection to proceed to initiate HR, whereas 53BP1/RIF1 blocks localization of BRCA1 to DSBs in G1 [50, 51] . The inability of BRCA1 to form detectable DSB-induced foci in G1 suggests that BRCA1 should not be able to modulate C-NHEJ in this cell cycle phase. However, we propose that BRCA1 differentially influences specific DSB repair processes by either directly interacting with proteins at the sites of DSBs or in the vicinity of the DSB site in a cell cycle phase-dependent manner. This is supported by a recent study demonstrating that BRCA1 is recruited to both the DSB site and to regions surrounding the DSB [52] . BRCA1 is recruited directly to the vicinity of the DSB through an interaction with the MRN complex factor, Nijmegen Breakage Syndrome 1 Protein (NBS1), and this interaction is required for precise re-ligation of genomic DSBs by C-NHEJ in G1. We hypothesize that BRCA1 modulates C-NHEJ directly at the DSB site in G1 by influencing the dynamics of Ku70/80 at DSB sites (Fig. 2 ) [7] . We predict that the fraction of BRCA1, which is localized in the flanking regions of the DSB and not at the DSB site, is disrupted by 53BP1/RIF1. Thus, 53BP1/RIF1 does not influence the ability of BRCA1 to regulate precise end-joining by C-NHEJ. However, Ku80's function in C-NHEJ in G1 may only be partially regulated by BRCA1, because silencing of BRCA1 does not completely disrupt Ku80 binding to DSB ends; also, the effect of Ku80 loss on C-NHEJ is superior to that of BRCA1 loss [7] . We speculate that C-NHEJ may contain subset/multiple pathways, those that are inherently precise or error-prone. If BRCA1 modulates only a subset of C-NHEJ in G1 phase that drives precise end-joining, this raises a number of questions. For example, the factors required for this repair process are still unclear. Also, it is still unknown if BRCA1 regulates specific enzymes required for this subset of C-NHEJ, and if this is dependent on the nature of the DSB (i.e. 'easily ligatable ends' vs 'ends that require processing'). The requirement for BRCA1 in a subset of C-NHEJ, which is inherently precise, may also explain the contradictory reports in regards to BRCA1's role in C-NHEJ. Last, it is also possible that BRCA1 does not actually modulate C-NHEJ directly, but promotes precise end-joining by blocking A-NHEJ in G1 phase. BRCA1 inhibits the nuclease activity of MRE11 and the MRN complex in vitro [53] . As MRE11 nuclease activity is required for the formation of microhomology in A-NHEJ, BRCA1 may attenuate MRE11-dependent DNA end processing to drive DSB repair towards the more precise C-NHEJ pathway in G1 phase. It will be of great interest to determine if and how BRCA1 promotes precise rejoining of DSBs in G1 directly. In S phase, BRCA1 plays a number of roles that promote HR [12, 13] . One key role is the stimulation of HR by attenuating C-NHEJ in this cell cycle phase to block inappropriate repair of replication-associated DSBs. This is supported by studies indicating that the embryonic lethality, HR deficiency, and genomic instability associated with loss of BRCA1 in mouse models is driven by C-NHEJ in S phase, and that this can be rescued by genomic deletion of the pro-NHEJ factor 53BP1 [54, 55] . Furthermore, the SerineGlutamine (SQ) cluster between the N-and C-terminal domains of BRCA1 contains residues phosphorylated by ATM and ATR that are critical for HR. Mutations at these sites (S1387A, S1423A, S1457A and S1524A) shifted DSB repair from HR to NHEJ and abrogation of the G2/M checkpoint, leading to increased chromosomal Fig. 2 . In G1 phase, BRCA1, through its N-terminal interaction with Ku80, stabilizes Ku80 binding to DNA ends (favoring C-NHEJ) and inhibits end-processing activity of the MRN complex through its interaction with NBS1, preventing DSBs from being repaired by mutagenic A-NHEJ. In S/G2 phases, BRCA1 blocks the autophosphorylation of DNA-PKcs at S2056 through its C-terminal interaction with DNA-PKcs, preventing DSBs from being funneled to the C-NHEJ pathway. BRCA1's interaction with the CtIP and MRN complex accelerates end processing, thus driving the repair of DSBs to the HR pathway. i21 • BRCA1 in DNA end-joining aberrations and mitotic catastrophe [56] . Our recent data suggest that BRCA1 may also modulate C-NHEJ directly in S phase [57] . We found that DNA-PKcs interacts with BRCA1 independently of DNA damage, but that this interaction is specific for S phase of the cell cycle. DNA-PKcs autophosphorylation at serine 2056 is cell cycleregulated with phosphorylation at this site, high in G1 but markedly attenuated in S phase. This finding suggests that attenuating 2056 phosphorylation may modulate NHEJ specifically in this cell cycle phase. We demonstrated that autophosphorylation of DNA-PKcs at serine 2056 is attenuated in S phase by BRCA1 [57] . Blocking phosphorylation of DNA-PKcs at the serine 2056 cluster resulted in an increase in the DNA end processing required for HR, as observed via increased RPA and Rad51 focus formation. Our data suggest that BRCA1 attenuates NHEJ specifically by abrogating DNA-PKcs autophosphorylation. This is different from BRCA1's role in NHEJ in G1 because the interactions of BRCA1 with Ku80 and DNA-PKcs are distinct, with BRCA1 interacting with Ku80 in G1 phase and with DNAPKcs in S phase. Furthermore, Ku80 interacts with the N-terminus of BRCA1 and DNA-PKcs interacts with the C-terminal region of BRCA1, and this interaction occurs even in the absence of Ku70/80. Hence, BRCA1 influences C-NHEJ in a cell cycle phase-dependent manner via differential interaction with Ku80 (G1 phase) and DNAPKcs (S phase). We believe these interactions play important roles in driving precise repair in all cell cycle phases, promoting precise C-NHEJ and blocking erroneous A-NHEJ in G1 and driving HR and attenuating C-NHEJ in S/G2 phases (Fig. 2) .
CONCLUSION
We propose that BRCA1 promotes precise DSB repair across all cell cycle phases. In the absence of HR in G1, BRCA1's interactions with Ku80 and the MRN complex positively influences the relatively precise C-NHEJ pathway, while negatively regulating mutagenic A-NHEJ. In S phase, the interaction of BRCA1 with DNA-PKcs inhibits C-NHEJ and drives pathway choice towards the accurate HR pathway (Fig. 2) . BRCA1 is thus a critical factor driving repair pathway choice and is required for a cell's ability to maintain genomic stability. In conclusion, BRCA1 drives precise DSB repair while negatively regulating the error-prone pathways. It is this function that promotes BRCA1's roles as a tumor suppressor and a driver of genomic stability. The role of BRCA1 in DNA damage response, with emphasis on accurate repair of genomic insults, provides a better understanding of the etiology of BRCA1-associated tumorigenesis. It also provides a solid platform for the development of therapeutic approaches, some of which have already entered the clinical setting.
